A Single Picture Does Not Say It All: A Case for Comprehensive Biomarker Use in Cancer Research
During the Virtual Biomarkers Congress Eitan Akirav presented A Single Picture Does Not Say It All, a case for comprehensive biomarker use within oncology research. Did you miss out on his presentation during the conference? Now you can submit the form below to watch it at your own leisure!
Nonnegotiable Central Laboratory Capabilities for I/O Clinical Trial Success
In immuno-oncology (I/O), meeting budget and timeline expectations in the journey from translational research to commercialization is a challenge. You need expert, integrated clinical laboratory and diagnostic solutions delivered by top scientists who will help you assess needs and generate early insights that optimize your protocol.
What else should you look for in a clinical laboratory partner? Along with access to a sizable patient database, impeccable performance across the globe, and I/O experience, three main testing capabilities are mandatory for success in this field: immunohistochemistry, flow cytometry, and next generation sequencing.
Biomarkers in Immuno-Oncology: Identifying and Implementing Biomarker Testing from Exploratory Research to Clinical Trials
Biomarkers are at the heart of Immuno-Oncology. In this webinar, we will walk you through three case studies to highlight the importance of biomarkers, using different methodologies. Why do some patients respond better to I/O therapeutics than others? What is Flow Cytometry’s role in immunophenotyping? Where does Immunohistochemistry come in? What is the Tumor Mutation Burden, how does it impact I/O research?
Amanda Finan, Head of IHC R&D Cerba Research, Nithianandan Selliah, Global Head of Flow Cytometry Cerba Research, and Raouf Ben Abdelali, Head of the Hematology and Oncology Division, Cerba Laboratory will guide you through their respective fields of expertise and answer the above questions.